Toward the use of buprenorphine in infants for neonatal opioid withdrawal syndrome: summary of an NIH workshop (original) (raw)

The workshop aimed to examine the use of buprenorphine for treating neonatal opioid withdrawal syndrome (NOWS) in infants due to the rising public health crisis of opioid use among pregnant women. Current practices mainly involve morphine, but emerging evidence suggests buprenorphine may be more effective. Key discussions included the variability of drug exposure in infants, limitations in existing studies, ongoing clinical trials, and the importance of pragmatic trial designs to advance understanding of buprenorphine's role in NOWS treatment.